US Patent 12,097,206: Claim Scope, Patent Strength, and Fenfluramine Patent Landscape

US Patent 12,097,206 protects specific combination-treatment methods for Dravet syndrome using fenfluramine with stiripentol and clobazam. The patent does not broadly cover fenfluramine, stiripentol, clobazam, or their separate use. Its commercial scope is concentrated on patients receiving the established stiripentol-plus-clobazam regimen, with fenfluramine added at defined daily doses.

The strongest practical coverage is claim 1, which applies to Dravet syndrome patients receiving fenfluramine at 0.2 to 0.5 mg/kg/day together with stiripentol and clobazam. Claims 3 and 5 narrow coverage to specified epilepsy-associated gene mutations. Claim 2 adds prior-treatment nonresponse but contains a reversed dose range that creates a potential claim-construction and definiteness issue.

What does US Patent 12,097,206 protect?

The patent protects a multi-drug treatment method requiring all of the following:

A patient diagnosed with Dravet syndrome, or, for claims 4 and 5, a patient identified through a mutation associated with Dravet syndrome.
Administration of fenfluramine or a pharmaceutically acceptable salt.
Administration of stiripentol or a pharmaceutically acceptable salt.
Administration of clobazam or a pharmaceutically acceptable salt.
Use of the regimen to treat, prevent, or ameliorate seizures.
For some claims, a specified fenfluramine dose.
For claims 2 and 3, prior-treatment nonresponse.
For claims 3 and 5, the presence of one of eight listed gene mutations.

The patent is therefore a regimen and patient-selection patent. It is not a composition-of-matter patent covering fenfluramine itself.

Claim-by-claim scope

Claim	Principal limitation	Practical scope	Main vulnerability
1	Dravet syndrome; fenfluramine 0.2-0.5 mg/kg/day; stiripentol; clobazam	Broadest claim in the set	Requires proof of all three drugs and dose range
2	Dravet syndrome; patient not responsive to prior treatment; fenfluramine dose stated as 0.5-0.2 mg/kg/day; stiripentol; clobazam	Intended to cover treatment-resistant or inadequately controlled patients	Reversed dose range may create indefiniteness or construction problems
3	Claim 2 plus mutation in SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD, or PCDH19	Genotype-defined subset of claim 2	Requires genetic evidence and satisfaction of claim 2
4	Determining a mutation associated with Dravet syndrome; administering fenfluramine at 0.2 mg/kg/day, stiripentol, and clobazam	Genotype-directed treatment, without expressly requiring a formal Dravet diagnosis	Mutation-association language may be disputed; exact dose is narrow
5	Claim 4 plus one of the eight listed mutations	Narrowest genotype-specific pathway	Limited patient population and testing proof

How should the fenfluramine dose in claim 2 be interpreted?

Claim 2 states a fenfluramine dose of “0.5 mg/kg/day to 0.2 mg/kg/day.” A numerical range ordinarily proceeds from the lower value to the higher value. The likely intended range is 0.2 to 0.5 mg/kg/day, consistent with claim 1 and the dosing structure described in the claims.

The wording creates three possible legal outcomes:

A court may treat the language as an obvious drafting error and construe it as 0.2 to 0.5 mg/kg/day.
A court may find that the range is internally ambiguous or indefinite.
A court may construe the claim narrowly, potentially limiting the claim to an interpretation that does not materially expand beyond the literal text.

The issue has limited effect on claim 1, which separately recites the correctly ordered 0.2 to 0.5 mg/kg/day range. It matters more for claim 2 because the additional “not responsive to prior treatment” limitation may provide commercially useful coverage against patients who remain uncontrolled on standard therapy.

How do the claims map onto the Fintepla treatment regimen?

Fintepla is the branded fenfluramine product marketed by UCB following UCB’s acquisition of Zogenix. The FDA-approved Dravet syndrome regimen uses fenfluramine as adjunctive therapy. Stiripentol and clobazam are recognized components of Dravet syndrome treatment, and the patent targets their use with fenfluramine.

The claims are most relevant where a patient:

Has Dravet syndrome;
Receives stiripentol;
Receives clobazam;
Adds Fintepla to the existing regimen; and
Receives fenfluramine within the claimed daily-dose range.

A prescription record, medication administration record, pharmacy data, clinical protocol, or product label can establish the drug components and dose. The most difficult elements to prove may be:

Whether the patient is “not responsive to prior treatment”;
Whether the patient has one of the listed mutations;
Whether the administered dose falls within the claimed range; and
Whether the claimed regimen actually ameliorates seizures.

The final “whereby” clauses state the treatment result. Their effect will depend on claim construction. A defendant may argue that the result is merely an intended consequence of treatment. The patent owner may argue that seizure amelioration is a required therapeutic outcome.

What is the patent strength of US 12,097,206?

The patent has meaningful commercial value but a narrower enforceability profile than a compound patent.

Strengths

The strongest features are:

The claims identify a concrete three-drug regimen.
The regimen is tied to a defined disease, Dravet syndrome.
Claim 1 uses a clinically recognizable fenfluramine dose range.
The claims can cover addition of fenfluramine to patients already receiving stiripentol and clobazam.
Claims 3 through 5 create genotype-specific positions that may be useful in clinical-trial protocols and precision-medicine treatment pathways.
The patent may cover clinical use even if a future product has no patent on fenfluramine itself.

Weaknesses

The principal weaknesses are:

The components are individually known therapies or known drug products.
Stiripentol and clobazam are established Dravet syndrome treatments.
Fenfluramine has an established role in Dravet syndrome.
The combination may face obviousness arguments based on the known use of the three agents in the same disease.
The “effective dose” language is open-ended for stiripentol and clobazam.
The mutation list may be challenged if the specification does not adequately demonstrate that each listed mutation predicts response.
Claim 2 contains the reversed dose range.
Method claims generally require proof that the claimed conduct occurred, unlike a product claim that can be infringed by making, using, selling, or importing the product.

The patent’s strength will depend heavily on the specification’s clinical data, the prosecution history, the cited prior art, and whether the claims survived examination with narrowing amendments.

What prior art is most relevant?

The most material prior-art categories are:

Fenfluramine in Dravet syndrome

Earlier publications and patent applications describing fenfluramine for seizure reduction in Dravet syndrome are likely to be central to novelty and obviousness analysis. If those references disclose fenfluramine as adjunctive therapy but do not disclose simultaneous use with stiripentol and clobazam at the claimed dose, the patent may rely on the combination and patient-selection limitations.

Stiripentol and clobazam in Dravet syndrome

The use of stiripentol with clobazam is well established. A prior-art reference showing that combination would not necessarily anticipate the claims because it would still need to disclose fenfluramine and the other limitations. It can, however, support an obviousness argument that adding fenfluramine to a known Dravet syndrome regimen was predictable.

Genetic causes of Dravet syndrome

SCN1A is strongly associated with Dravet syndrome. The other listed genes have varying levels of association with Dravet-spectrum epilepsy. Prior genetic literature may challenge the breadth of claims 3 and 5 if it shows that the listed mutations were already recognized as associated with the disease.

Treatment-resistant patients

Prior clinical studies describing fenfluramine in patients uncontrolled by prior antiseizure medicines may be relevant to claim 2. The “not responsive to prior treatment” limitation may not provide substantial patentable distinction if treatment-resistant Dravet patients were the same population enrolled in earlier fenfluramine studies.

Does the patent cover fenfluramine monotherapy?

No. The supplied claims require the administration of fenfluramine together with stiripentol and clobazam.

A company or healthcare provider using fenfluramine without stiripentol would not satisfy the express combination limitation. Use with clobazam but without stiripentol would also fall outside the claims. The same applies to use with stiripentol but without clobazam.

The patent also does not cover every fenfluramine dose. Claims 1 and 2 require the stated range, while claim 4 requires exactly 0.2 mg/kg/day. A dose outside those limitations may avoid literal infringement, although doctrine-of-equivalents arguments could become relevant depending on the difference and prosecution history.

What formulations are protected by the patent?

The claims do not recite a particular formulation, dosage form, excipient, container, concentration, or delivery device. They cover administration of fenfluramine or a pharmaceutically acceptable salt.

Accordingly, the claims may reach use of:

An oral fenfluramine solution;
A tablet or capsule, if clinically used;
A generic fenfluramine formulation;
A salt form that qualifies as pharmaceutically acceptable; or
Another dosage form delivering the claimed dose.

The patent does not, based on the supplied claims, protect the formulation technology itself. Separate formulation, concentration, stability, manufacturing, or device patents would need to be analyzed independently.

What is the FDA and Orange Book relevance?

Fintepla received FDA approval for seizures associated with Dravet syndrome in 2020 and later for seizures associated with Lennox-Gastaut syndrome. The FDA-approved product is subject to a controlled-distribution framework because of fenfluramine’s cardiovascular risks. The FDA label includes warnings concerning pulmonary arterial hypertension and valvular heart disease and requires risk-management controls.[1]

US Patent 12,097,206 is relevant to Orange Book analysis only if it is listed for the relevant approved drug and use. A method-of-use patent can be listed with an FDA use code, but the patent number alone does not establish:

That the patent is listed in the Orange Book;
The applicable use code;
Whether the listing covers Dravet syndrome;
Whether the listing covers the stiripentol-plus-clobazam combination; or
Whether an ANDA applicant must certify under Paragraph IV.

The key regulatory distinction is between the approved Fintepla label and the narrower patent claims. FDA approval does not itself determine infringement. Conversely, an Orange Book listing does not establish validity or enforceability.

When does fenfluramine lose regulatory and patent exclusivity?

Regulatory exclusivity and patent exclusivity are separate.

Regulatory exclusivity

Fintepla’s Dravet syndrome approval received orphan-drug exclusivity under the Orphan Drug Act. Orphan exclusivity generally lasts seven years from approval for the same indication, subject to statutory exceptions. The FDA approval date for Dravet syndrome was June 25, 2020, placing the ordinary seven-year orphan period in June 2027.[1][2]

Other exclusivity periods may apply to later indications or pediatric studies. Their effect must be evaluated separately from the patent term.

Patent term

The expiration date for US Patent 12,097,206 depends on its earliest effective nonprovisional priority date, patent-term adjustment, terminal disclaimers, and any patent-term extension. A reliable expiration assessment must use the issued patent and USPTO prosecution record rather than the claim text alone.

If the patent claims priority to an application filed in the late 2010s, its ordinary 20-year term could extend into the late 2030s, subject to adjustment and disclaimer rules. The patent term should not be equated with Fintepla’s orphan exclusivity period.

Are generic companies likely to challenge this patent under Paragraph IV?

A Paragraph IV challenge is commercially plausible if the patent is listed for Fintepla and a generic applicant seeks approval for an indication or labeling that overlaps the patented regimen.

Potential invalidity positions include:

Obviousness based on known fenfluramine use in Dravet syndrome;
Obviousness based on the established stiripentol-clobazam regimen;
Lack of written description for all listed mutations;
Lack of enablement across the full patient and dosing scope;
Indefiniteness arising from claim 2’s reversed dose range;
Anticipation by clinical or patent publications disclosing the three-drug regimen; and
Ineligible or non-novel treatment-result language, depending on claim construction.

A generic applicant could also pursue a section viii “skinny label” strategy if it can omit the patented use from labeling and marketing. That route becomes difficult if the approved label itself necessarily instructs use of fenfluramine with stiripentol and clobazam or if the patent is interpreted to cover the principal approved use.

What generic launch scenarios exist?

Scenario	Commercial result	Patent risk
Generic omits the patented combination indication	Earlier launch may be possible	Depends on labeling and induced-infringement exposure
Generic includes Dravet syndrome but excludes stiripentol-plus-clobazam use	Partial market entry	Claim 1 may still be avoided if the exclusion is effective
Generic challenges listed patent under Paragraph IV	Litigation and possible 30-month stay	Validity and infringement become central
Generic launches after patent expiry	Full market entry for the covered use	Regulatory exclusivity may still matter if separate
Authorized generic or license deal	Earlier competitive supply under patent-holder control	Depends on settlement and license terms

Which companies are commercially exposed?

UCB has the primary branded exposure through Fintepla commercialization. Generic manufacturers of fenfluramine would face the principal risk if they seek an indication or label overlapping the claimed use.

Companies marketing stiripentol or clobazam are less directly exposed because the claims require fenfluramine as part of the combination. Exposure could arise through induced infringement theories if a company actively instructs or promotes the complete patented regimen.

The patent does not materially affect unrelated antiseizure medicines unless they are used as substitutes for one of the three claimed components.

Does the patent create biosimilar risk?

No conventional biosimilar issue exists. Fenfluramine, stiripentol, and clobazam are small-molecule drugs. Competition would proceed through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.

The relevant risks are generic substitution, Paragraph IV litigation, section viii labeling, formulation patents, and regulatory exclusivity.

What litigation and settlement issues should be monitored?

The material events are:

Orange Book listing and any use-code changes;
ANDA Paragraph IV notices;
District-court complaints under the Hatch-Waxman statute;
Declaratory-judgment actions;
Claim-construction rulings concerning the dose range;
Challenges to the mutation limitations;
Settlements involving delayed generic entry;
Authorized-generic licenses; and
Any Federal Circuit decision affecting method-of-treatment claim enforcement.

A settlement could permit a generic launch before patent expiry while preserving the patent owner’s control over the combination indication. The economic value of such a settlement would depend on Fintepla sales attributable to Dravet syndrome, the proportion of patients receiving stiripentol and clobazam, and the strength of the listed patent claims.

How does US Patent 12,097,206 compare with compound and formulation patents?

Patent type	Typical scope	Relative strength
Compound patent	Covers the active molecule or defined chemical class	Usually strongest
Salt or solid-state patent	Covers a particular chemical form	Strong if commercially necessary
Formulation patent	Covers concentration, excipients, stability, or delivery	Moderate to strong, depending on design-around options
Method-of-use patent	Covers a disease, dose, genotype, or treatment regimen	Narrower and more fact-dependent
Combination-treatment patent	Covers simultaneous or sequential use of multiple drugs	Commercially useful but vulnerable to obviousness
Manufacturing patent	Covers synthesis or purification process	Strong against process users, limited against alternative processes

US Patent 12,097,206 is a combination method-of-use patent with genotype and dosing subclaims. It can extend protection beyond an earlier compound or indication patent, but it does not prevent all generic fenfluramine sales.

Key Takeaways

US Patent 12,097,206 targets fenfluramine used with stiripentol and clobazam for Dravet syndrome.
Claim 1 is the broadest and commercially most important claim in the supplied set.
Claims 3 and 5 narrow protection to patients with specified epilepsy-associated gene mutations.
Claim 2’s “0.5 to 0.2 mg/kg/day” language creates a material drafting and claim-construction issue.
The patent does not cover fenfluramine monotherapy or every fenfluramine formulation.
Generic competition would involve ANDA litigation, Paragraph IV certification, and potentially a section viii carve-out, not biosimilar litigation.
The main validity risks are obviousness, written description, enablement, and indefiniteness.
The patent’s remaining term must be calculated from the USPTO patent record, including priority, patent-term adjustment, and any terminal disclaimer.
The FDA’s orphan exclusivity period for the original Dravet syndrome approval generally runs from June 25, 2020, to June 25, 2027, subject to applicable statutory extensions and exceptions.

FAQs

Can a physician infringe US Patent 12,097,206 by prescribing Fintepla?

Potentially, if the prescription directs the complete claimed regimen and satisfies the disease, dose, and patient limitations. Direct infringement analysis depends on who performs each claimed step and the governing case law.

Does testing for an SCN1A mutation create infringement risk by itself?

No. The claims require more than genetic testing. They require administration of fenfluramine, stiripentol, and clobazam under the specified treatment conditions.

Can a generic avoid the patent by changing the fenfluramine dose?

Possibly, if the changed dose falls outside the literal claim range and no doctrine-of-equivalents theory applies. Claim 4 is particularly narrow because it recites 0.2 mg/kg/day.

Does the patent cover treatment of Lennox-Gastaut syndrome?

The supplied claims require Dravet syndrome or a mutation associated with Dravet syndrome. They do not expressly cover Lennox-Gastaut syndrome.

Is the patent likely to block all generic fenfluramine products?

No. Its claims are limited to a specific combination regimen and patient population. A generic could still face other listed patents, regulatory exclusivity, or induced-infringement theories, but this patent alone does not cover every fenfluramine product or use.

References

U.S. Food and Drug Administration. (2024). Fintepla (fenfluramine) oral solution: Prescribing information.
U.S. Food and Drug Administration. (2020). FDA approves first drug to treat seizures associated with Dravet syndrome.
U.S. Patent No. 12,097,206. (2024). Methods of treating seizures associated with Dravet syndrome. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014261329	⤷ Start Trial
Australia	2019203448	⤷ Start Trial
Australia	2019203832	⤷ Start Trial
Australia	2020267264	⤷ Start Trial
Brazil	112015027282	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,097,206

Which drugs does patent 12,097,206 protect, and when does it expire?

Summary for Patent: 12,097,206